Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

被引：82

作者：

Honda, Yasushi ^{[1
]}

Kessoku, Takaomi ^{[1
]}

Sumida, Yoshio ^{[2
]}

Kobayashi, Takashi ^{[1
]}

Kato, Takayuki ^{[1
]}

Ogawa, Yuji ^{[1
]}

Tomeno, Wataru ^{[1
]}

Imajo, Kento ^{[1
]}

Fujita, Koji ^{[1
]}

Yoneda, Masato ^{[1
]}

Kataoka, Koshi ^{[3
]}

Taguri, Masataka ^{[3
]}

Yamanaka, Takeharu ^{[3
]}

Seko, Yuya ^{[4
]}

Tanaka, Saiyu ^{[5
]}

Saito, Satoru ^{[1
]}

Ono, Masafumi ^{[6
]}

Oeda, Satoshi ^{[7
]}

Eguchi, Yuichiro ^{[7
]}

Aoi, Wataru ^{[8
]}

Sato, Kenji ^{[9
]}

Itoh, Yoshito ^{[4
]}

Nakajima, Atsushi ^{[1
]}

机构：

[1] Yokohama City Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Yokohama, Kanagawa, Japan

[2] Aichi Med Univ, Div Hepatol & Pancreatol, Dept Internal Med, Nagakute, Aichi, Japan

[3] Yokohama City Univ, Dept Biostat, Grad Sch Med, Yokohama, Kanagawa, Japan

[4] Kyoto Prefectural Univ Med, Dept Gastroenterol & Hepatol, Kyoto, Japan

[5] Nara City Hosp, Ctr Digest & Liver Dis, Nara, Japan

[6] Kochi Med Sch, Dept Gastroenterol & Hepatol, Kochi, Japan

[7] Saga Univ Hosp, Liver Ctr, Saga, Japan

[8] Kyoto Prefectural Univ, Grad Sch Life & Environm Sci, Div Appl Life Sci, Kyoto, Japan

[9] Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Kyoto, Japan

来源：

BMC GASTROENTEROLOGY | 2017年 / 17卷

关键词：

Nonalcoholic fatty liver disease; Glutathione; Controlled attenuation parameter; VITAMIN-E; TRANSIENT ELASTOGRAPHY; METABOLIC SYNDROME; IRON DEPLETION; STEATOHEPATITIS; SUPPLEMENTATION; METAANALYSIS; PREVENTION; MORTALITY; INCREASE;

D O I：

10.1186/s12876-017-0652-3

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Glutathione plays crucial roles in the detoxification and antioxidant systems of cells and has been used to treat acute poisoning and chronic liver diseases by intravenous injection. This is a first study examining the therapeutic effects of oral administration of glutathione in patients with nonalcoholic fatty liver disease (NAFLD). Methods: The study was an open label, single arm, multicenter, pilot trial. Thirty-four NAFLD patients diagnosed using ultrasonography were prospectively evaluated. All patients first underwent intervention to improve their lifestyle habits (diet and exercise) for 3 months, followed by treatment with glutathione (300 mg/day) for 4 months. We evaluated their clinical parameters before and after glutathione treatment. We also quantified liver fat and fibrosis using vibration-controlled transient elastography. The primary outcome of the study was the change in alanine aminotransferase (ALT) levels. Results: Twenty-nine patients finished the protocol. ALT levels significantly decreased following treatment with glutathione for 4 months. In addition, triglycerides, non-esterified fatty acids, and ferritin levels also decreased with glutathione treatment. Following dichotomization of ALT responders based on a median 12.9% decrease from baseline, we found that ALT responders were younger in age and did not have severe diabetes compared with ALT non-responders. The controlled attenuation parameter also decreased in ALT responders. Conclusions: This pilot study demonstrates the potential therapeutic effects of oral administration of glutathione in practical dose for patients with NAFLD. Large-scale clinical trials are needed to verify its efficacy.

引用

页数：8

共 28 条

[1] Effects of Oral Glutathione Supplementation on Systemic Oxidative Stress Biomarkers in Human Volunteers [J].